BURLINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten
public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds
from this offering are expected to be approximately $77.0 million, before deducting underwriting discounts and commissions and
estimated offering expenses payable by Flexion. The offering is expected to close on or about June 13, 2016, subject to
customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 825,000 additional
shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Wells Fargo Securities, RBC Capital Markets and BMO Capital Markets are acting as joint book-running managers. Janney Montgomery
Scott and Laidlaw & Company (UK) Ltd. are acting as co-managers.
The shares of common stock described above are being offered pursuant to a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating
to the offering, when available, may also be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375
Park Avenue, New York, New York 10152, or by email at cmclientsupport@wellsfargo.com, or by telephone at (800) 326-5897; from RBC
Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281,, or by telephone at (877)
822-4089, or by email at equityprospectus@rbccm.com; or from BMO Capital Markets Corp., 3 Times Square, 25th Floor, New
York, NY 10036, Attention: Equity Syndicate Department, or by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Flexion’s securities. No
offer, solicitation or sale will be made in any state or other jurisdiction in which such offer, solicitation or sale would be
unlawful.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being
investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections
for knee OA annually.
Forward-Looking Statements
Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements
relating to expectations regarding the completion, timing and proceeds of the public offering, are forward-looking statements.
These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and
are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without limitation, risks associated with market conditions and
the satisfaction of customary closing conditions related to the offering; and other risks and uncertainties described in our
filings with the SEC, including under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent
filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we
undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 dcarey@lazarpartners.com Media Contact Mariann Caprino TogoRun T: 917.242.1087 M.Caprino@togorun.com Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 fdriscoll@flexiontherapeutics.com
